News

July 20, 2012 — The online clinical drug resource Drugs.com released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood thinners, proton-pump inhibitors, antipsychotics...

Mercator MedSystems, a medical technology company whose platform Micro-Infusion Catheter technology announced preliminary results of its DANCE clinical trial that continues to follow...

Over the past decade there have been several advancements in prothrombin time (PT)/international normalized ration (INR) point-of-care testing (POCT) devices. This is usually performed at an...

June 22, 2012 — The the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee voted in May against recommending approval of expanding the indication for...

June 11, 2012 — Boehringer Ingelheim Pharmaceuticals Inc. announced that the Pradaxa (dabigatran etexilate mesylate) capsules prescribing information has been updated to affirm that "Pradaxa 150...

June 1, 2012 — Kona Medical Inc. announced it has raised $30 million in Series C financing to advance its novel hypertension therapy. Existing investors Essex Woodlands, Domain Associates,...

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents,...

May 18, 2012 -- St. Jude Medical Inc., a global medical device company, announced that preliminary data demonstrated the company’s EnligHTN renal denervation system was safe and effective for the...

The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients...

May 15, 2012 – St. Jude Medical Inc., a global medical device company, announced CE mark approval and launch of its EnligHTN renal denervation system during EuroPCR. Renal denervation is a...

May 15, 2012 — Reaching out to patients with a few simple phone calls significantly improves the likelihood they’ll continue to take critically important medication that...

May 9, 2012 — Sound Interventions Inc. announced the successful completion of the company's first-in-human clinical trial to treat resistant hypertension, SOUND-ITV.

May 4, 2012 - Medtronic Inc. announced six-month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity renal...

May 2, 2012 — Vessix Vascular Inc. announced this week that it has received CE mark approval for its V2 Renal Denervation System for the treatment of hypertension. Renal denervation is a...

April 24, 2012—Providing more guidance to clinicians on the provision of optimal patient care, the American College of Cardiology Foundation (ACCF), American Heart Association (AHA) and American...

April 19, 2012 — Spherix Inc. announced results from its recently completed studies using near-infrared spectroscopy on autopsy samples from humans who had confirmed cardiovascular disease....

ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked Paradise (percutaneous renal denervation system) ultrasound platform, which is...

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly...

April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment...

It seems a picture is worth more than a thousand words for people who see evidence of coronary artery disease, the most common type of heart disease in men and women. Simply seeing a build-up of...